IGC Pharma to Participate in Fireside Chat with Ascendiant Capital Markets

Rhea-AI Summary

IGC Pharma (NYSE American: IGC) has announced its participation in a fireside chat hosted by Ascendiant Capital Markets scheduled for January 23, 2025, at 1:00 pm ET. CEO Ram Mukunda and CCO Claudia Grimaldi will lead the discussion.

The management team will provide updates on several key areas including:

• Recent progress in the company's Alzheimer's pipeline
• Strategic expansion into metabolic disorders
• Integration of artificial intelligence in drug discovery

The discussion will also cover upcoming milestones, including:

• New clinical trial launches
• Preclinical developments
• Efforts to expand their addressable market in Alzheimer's disease and weight loss therapies

POTOMAC, MD / ACCESSWIRE / January 13, 2025 / IGC Pharma, Inc (NYSE American:IGC) ("IGC" or the "Company"), today announced that CEO Ram Mukunda and CCO Claudia Grimaldi will be participating in a fireside chat hosted by Ascendiant Capital Markets on Thursday, January 23, 2025, at 1:00 pm ET.

During the session, IGC Pharma's management will provide insights into the Company's recent progress, including advancements in its Alzheimer's pipeline, strategic expansion into metabolic disorders, and the integration of artificial intelligence in drug discovery. They will also discuss key upcoming milestones, including new clinical trial launches, preclinical developments, and efforts to broaden the Company's addressable market in Alzheimer's disease and weight loss therapies.

To register and join the fireside chat visit: LINK

About IGC Pharma (dba IGC):
IGC Pharma is an AI-powered, clinical-stage biotechnology company focused on developing innovative treatments for Alzheimer's disease and transforming patient care with fast-acting, safe, and effective solutions. Our portfolio includes the TGR family, including TGR-63, which targets amyloid plaques, a hallmark of Alzheimer's. The IGC-C and IGC-M platforms are advancing in preclinical studies, focusing on metabolic disorders, tau proteins, early plaque formation, and multiple disease hallmarks. Our lead therapeutic candidate, IGC-AD1, is a cannabinoid-based treatment currently in a Phase 2 trial for agitation in dementia associated with Alzheimer's (clinicaltrials.gov, NCT05543681). Interim data for IGC-AD1 demonstrated that it has the potential to transform patient care by offering faster-acting and more effective relief compared to traditional medications. Additionally, our AI models are designed to predict potential biomarkers for the early detection of Alzheimer's, optimize clinical trials, and predict receptor affinity, among others. With 28 patent filings and a commitment to innovation, IGC Pharma is dedicated to advancing pharmaceutical treatments and improving the lives of those affected by Alzheimer's and related conditions.

Forward-Looking Statements
This press release contains forward-looking statements. These forward-looking statements are based largely on IGC Pharma's expectations and are subject to several risks and uncertainties, certain of which are beyond IGC Pharma's control. Actual results could differ materially from these forward-looking statements as a result of, among other factors, the Company's failure or inability to commercialize one or more of the Company's products or technologies, including the products or formulations described in this release, or failure to obtain regulatory approval for the products or formulations, where required, or government regulations affecting AI or the AI algorithms not working as intended or producing accurate predictions; general economic conditions that are less favorable than expected; the FDA's general position regarding cannabis- and hemp-based products; and other factors, many of which are discussed in IGC Pharma's U.S. Securities and Exchange Commission ("SEC") filings. IGC incorporates by reference its Annual Report on Form 10-K filed with the SEC on June 24, 2024, and on Form 10-Q filed with the SEC on August 7, 2024, as if fully incorporated and restated herein. Considering these risks and uncertainties, there can be no assurance that the forward-looking information contained in this release will occur.

Contact Information
Rosalyn Christian / Walter Frank
IMS Investor Relations
igc@imsinvestorrelations.com
(203) 972-9200

SOURCE: IGC Pharma, Inc.

View the original press release on accesswire.com

FAQ

When is IGC Pharma's fireside chat with Ascendiant Capital Markets scheduled for?

IGC Pharma's fireside chat with Ascendiant Capital Markets is scheduled for Thursday, January 23, 2025, at 1:00 pm ET.

What key topics will be discussed during IGC Pharma's January 2025 fireside chat?

The fireside chat will cover IGC Pharma's Alzheimer's pipeline progress, expansion into metabolic disorders, AI integration in drug discovery, upcoming clinical trials, and developments in weight loss therapies.

Which therapeutic areas is IGC Pharma currently focusing on according to the January 2025 announcement?

According to the announcement, IGC Pharma is focusing on Alzheimer's disease and weight loss therapies, with strategic expansion into metabolic disorders.

How is IGC Pharma incorporating artificial intelligence into its business?

IGC Pharma is integrating artificial intelligence into its drug discovery process, though specific details will be discussed during the upcoming fireside chat.

Who will represent IGC Pharma at the January 2025 Ascendiant Capital Markets fireside chat?

CEO Ram Mukunda and CCO Claudia Grimaldi will represent IGC Pharma at the fireside chat.